Paromomycin

Revision as of 11:48, 7 July 2017 by Mholtz (talk | contribs) (Text replacement - "qid" to "QID")
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Administration

  • Type: Amebicide
  • Dosage Forms: 250
  • Routes of Administration: Oral
  • Common Trade Names: Humatin

Adult Dosing

Intestinal amebiasis

  • 25-35mg/kg/day PO divided tid x5-10 days
    • Give with food

Hepatic encephalopathy

  • adjunct treatment: 1000mg PO QID x5-6 days
    • Give with food

Pediatric Dosing

Intestinal amebiasis

  • 25-35mg/kg/day PO divided tid x5-10 days

Special Populations

  • Poorly absorbed when given orally
  • Use during pregnancy has limited data

Renal Dosing

  • No change in dosing

Hepatic Dosing

  • No change in dosing

Contraindications

  • Allergy to class/drug
  • GI obstruction
  • caution if ulcerative colitis
  • caution if inflammatory bowel disease
  • caution if renal impairment

Adverse Reactions

Serious

  • nephrotoxicity
  • ototoxicity, auditory
  • ototoxicity, vestibular
  • neurotoxicity
  • neuromuscular blockade
  • malabsorption syndrome (prolonged use)
  • superinfection (prolonged use)
  • enterocolitis

Common

Pharmacology

  • Half-life: Unknown
  • Metabolism: CYP450
  • Excretion: Feces

Mechanism of Action

Bactericidal and amebicidal. Paromomycin binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis; it suppresses urease producing bacteria, reducing ammonia absorption from gut

Comments

See Also

References

UpToDate, Epocrates